RU2009112207A - Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью - Google Patents

Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью Download PDF

Info

Publication number
RU2009112207A
RU2009112207A RU2009112207/04A RU2009112207A RU2009112207A RU 2009112207 A RU2009112207 A RU 2009112207A RU 2009112207/04 A RU2009112207/04 A RU 2009112207/04A RU 2009112207 A RU2009112207 A RU 2009112207A RU 2009112207 A RU2009112207 A RU 2009112207A
Authority
RU
Russia
Prior art keywords
physiologically acceptable
compound
formula
acceptable solvate
pharmaceutical composition
Prior art date
Application number
RU2009112207/04A
Other languages
English (en)
Inventor
Кейт БИГГАДАЙК (GB)
Кейт Биггадайк
Дебора НИДХАМ (GB)
Дебора НИДХАМ
Original Assignee
Глаксо Груп Лимитед (GB)
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксо Груп Лимитед (GB), Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед (GB)
Publication of RU2009112207A publication Critical patent/RU2009112207A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1. Соединение формулы (I): ! ! или его физиологически приемлемый сольват. ! 2. Соединение формулы (I) по п.1 или его физиологически приемлемый сольват для применения в ветеринарии или в медицине человека. ! 3. Применение соединения формулы (I) по п.1 или его физиологически приемлемого сольвата для изготовления лекарства для лечения воспалительных и/или аллергических состояний. ! 4. Фармацевтическая композиция, содержащая соединение формулы (I) по п.1 или его физиологически приемлемый сольват, если требуется, в смеси с одним или более физиологически приемлемыми разбавителями или носителями. ! 5. Фармацевтическая аэрозольная композиция, содержащая соединение формулы (I) по п.1 или его физиологически приемлемый сольват и фторуглерод или водородсодержащий хлорфторуглерод в качестве пропеллента, возможно в комбинации с поверхностно-активным веществом и/или со-растворителем. ! 6. Фармацевтическая композиция по п.5, которая дополнительно содержит другой терапевтически активный агент. ! 7. Фармацевтическая композиция по п.6, в которой указанный другой терапевтически активный агент представляет собой агонист β2-адренорецепторов. ! 8. Способ лечения человека или животного с воспалительным и/или аллергическим состоянием, включающий введение указанному человеку или животному эффективного количества соединения формулы (I) по п.1 или его физиологически приемлемого сольвата.

Claims (8)

1. Соединение формулы (I):
Figure 00000001
или его физиологически приемлемый сольват.
2. Соединение формулы (I) по п.1 или его физиологически приемлемый сольват для применения в ветеринарии или в медицине человека.
3. Применение соединения формулы (I) по п.1 или его физиологически приемлемого сольвата для изготовления лекарства для лечения воспалительных и/или аллергических состояний.
4. Фармацевтическая композиция, содержащая соединение формулы (I) по п.1 или его физиологически приемлемый сольват, если требуется, в смеси с одним или более физиологически приемлемыми разбавителями или носителями.
5. Фармацевтическая аэрозольная композиция, содержащая соединение формулы (I) по п.1 или его физиологически приемлемый сольват и фторуглерод или водородсодержащий хлорфторуглерод в качестве пропеллента, возможно в комбинации с поверхностно-активным веществом и/или со-растворителем.
6. Фармацевтическая композиция по п.5, которая дополнительно содержит другой терапевтически активный агент.
7. Фармацевтическая композиция по п.6, в которой указанный другой терапевтически активный агент представляет собой агонист β2-адренорецепторов.
8. Способ лечения человека или животного с воспалительным и/или аллергическим состоянием, включающий введение указанному человеку или животному эффективного количества соединения формулы (I) по п.1 или его физиологически приемлемого сольвата.
RU2009112207/04A 2003-07-11 2009-04-03 Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью RU2009112207A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316290.6A GB0316290D0 (en) 2003-07-11 2003-07-11 Novel compounds
GB0316290.6 2003-07-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2005141226/04A Division RU2359973C2 (ru) 2003-07-11 2004-07-09 Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью

Publications (1)

Publication Number Publication Date
RU2009112207A true RU2009112207A (ru) 2010-10-10

Family

ID=27742019

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2005141226/04A RU2359973C2 (ru) 2003-07-11 2004-07-09 Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью
RU2005141064/04A RU2348645C2 (ru) 2003-07-11 2004-07-09 Специфическое глюкокортикостероидное соединение, обладающее противовоспалительной активностью
RU2009112207/04A RU2009112207A (ru) 2003-07-11 2009-04-03 Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью

Family Applications Before (2)

Application Number Title Priority Date Filing Date
RU2005141226/04A RU2359973C2 (ru) 2003-07-11 2004-07-09 Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью
RU2005141064/04A RU2348645C2 (ru) 2003-07-11 2004-07-09 Специфическое глюкокортикостероидное соединение, обладающее противовоспалительной активностью

Country Status (31)

Country Link
US (6) US7291609B2 (ru)
EP (3) EP2380898B1 (ru)
JP (3) JP4709751B2 (ru)
KR (2) KR101029207B1 (ru)
CN (3) CN1849330B (ru)
AR (2) AR045900A1 (ru)
AT (1) ATE467638T1 (ru)
AU (2) AU2004255855B2 (ru)
BR (2) BRPI0412526A (ru)
CA (2) CA2531905C (ru)
CY (2) CY1110149T1 (ru)
DE (1) DE602004027137D1 (ru)
DK (2) DK1644398T3 (ru)
ES (3) ES2400821T3 (ru)
GB (1) GB0316290D0 (ru)
HK (2) HK1089186A1 (ru)
HR (2) HRP20100359T1 (ru)
IL (3) IL172777A (ru)
IS (3) IS2776B (ru)
MA (2) MA27899A1 (ru)
MX (2) MXPA06000442A (ru)
MY (2) MY140987A (ru)
NO (2) NO333263B1 (ru)
NZ (2) NZ544576A (ru)
PL (2) PL1644398T3 (ru)
PT (2) PT1644397E (ru)
RU (3) RU2359973C2 (ru)
SI (2) SI1644398T1 (ru)
TW (2) TWI367888B (ru)
WO (2) WO2005005451A1 (ru)
ZA (2) ZA200600223B (ru)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0125259D0 (en) * 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0316290D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004025966A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs
DE102004025985A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estriol- und Estetrol-Prodrugs
WO2006072599A2 (en) * 2005-01-10 2006-07-13 Glaxo Group Limited Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions
US20090124588A1 (en) * 2005-01-10 2009-05-14 Glaxo Group Limited Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
JP2008534611A (ja) * 2005-03-30 2008-08-28 シェーリング コーポレイション 抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法
ATE552032T1 (de) 2005-07-14 2012-04-15 Lithera Inc Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ES2388351T3 (es) 2006-04-20 2012-10-11 Glaxo Group Limited Compuestos novedosos
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
JP2010506941A (ja) * 2006-10-17 2010-03-04 リセラ，インク． 甲状腺眼症の治療のための方法、組成物及び製剤
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
EP2285803A4 (en) 2008-05-23 2011-10-05 Amira Pharmaceuticals Inc Inhibitor of 5-Lipoxygenase Activating Protein
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
ES2542551T3 (es) 2009-03-09 2015-08-06 Glaxo Group Limited 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
US20120058984A1 (en) 2009-03-17 2012-03-08 Catherine Mary Alder Pyrimidine derivatives used as itk inhibitors
WO2010107957A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
SG174452A1 (en) 2009-03-19 2011-10-28 Merck Sharp & Dohme RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
US20120016011A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010107958A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
MX2011010072A (es) 2009-03-27 2011-10-06 Merck Sharp & Dohme Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen de la molecula de adhesion intercelular 1 usando acido nucleico corto de interferencia.
EP2411520A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20100273744A1 (en) 2009-04-24 2010-10-28 Paul Martin Gore Compounds
WO2010122088A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
EA021056B1 (ru) 2009-04-30 2015-03-31 Глаксо Груп Лимитед Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ, содержащая их фармацевтическая композиция и их применение в лечении расстройств, опосредованных ненадлежащей активностью pi3-киназ
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
SG175738A1 (en) 2009-05-29 2011-12-29 Pfizer Ltd Novel glucocorticoid receptor agonists
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
US20120238571A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Indazole derivatives as pi 3-kinase
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
EP2507223A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
JP2013517294A (ja) * 2010-01-15 2013-05-16 リセラ，インク． 凍結乾燥ケーキ製剤
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
HUE026059T2 (en) 2010-09-08 2016-05-30 Glaxosmithkline Ip Dev Ltd N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazol-6-yl ] Polymorphs and salts of 2 - (methyloxy) -3-pyridinyl] methanesulfonamide
EP2613781B1 (en) 2010-09-08 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Indazole derivatives for use in the treatment of influenza virus infection
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
JP5795643B2 (ja) 2010-10-21 2015-10-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
JP2013544794A (ja) 2010-10-21 2013-12-19 グラクソ グループ リミテッド アレルギー性障害、炎症性障害及び免疫障害に作用するピラゾール化合物
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
TW201231042A (en) 2010-11-24 2012-08-01 Lithera Inc Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
EA201391230A1 (ru) 2011-02-25 2014-01-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов trk
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
WO2012123312A1 (en) 2011-03-11 2012-09-20 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
WO2014198909A1 (en) 2013-06-14 2014-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Rac1 inhibitors for inducing bronchodilation
KR20160062179A (ko) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제
KR20160062178A (ko) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제
MX2016014859A (es) 2014-05-12 2017-06-27 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190161480A1 (en) 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
US11759472B2 (en) * 2017-11-21 2023-09-19 Cs Pharmaceuticals Limited Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
EP3713544A2 (en) 2017-11-21 2020-09-30 Axerovision, Inc. Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
EP4125919A1 (en) 2020-03-26 2023-02-08 GlaxoSmithKline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943124A (en) * 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
GB1384372A (en) 1971-01-20 1975-02-19 Glaxo Lab Ltd Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids
US3686978A (en) 1971-04-09 1972-08-29 Fairfied Mfg Co Inc Plantetary reduction wheel hub
GB1438940A (en) * 1972-07-19 1976-06-09 Glaxo Lab Ltd 17beta-haloalkoxycarbonyl-17alpha-oxysteroids
US4093721A (en) * 1974-08-30 1978-06-06 Glaxo Laboratories Limited Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
GB1514476A (en) 1974-08-30 1978-06-14 Glaxo Lab Ltd Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates
GB2137206B (en) * 1980-02-15 1985-04-03 Glaxo Group Ltd Androstane 17-carbothioc acid derivatives
US4996335A (en) * 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
SE449106B (sv) * 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
EP0334853B1 (en) * 1987-10-13 1993-06-09 BODOR, Nicholas S. Soft steroids having anti-inflammatory activity
US5990099A (en) 1988-10-31 1999-11-23 Alcon Laboratories, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
WO1993019749A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
AU692892B2 (en) 1994-06-15 1998-06-18 Wellcome Foundation Limited, The Enzyme inhibitors
US6172054B1 (en) 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
WO1997041867A1 (en) 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Use of steroid compounds to prevent non-cancerous tissue growth
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
US6245804B1 (en) * 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
WO1999016768A1 (en) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Benzofuran derivatives
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
CA2323771A1 (en) 1998-03-14 1999-09-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone pde iii/iv inhibitors
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
CA2371273A1 (en) 1999-05-04 2000-11-09 Andrew Fensome Tetracyclic progesterone receptor modulator compounds and methods
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6263209B1 (en) 1999-07-28 2001-07-17 Motorola, Inc. Method and apparatus in a wireless communication system for creating a learning function
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds
NZ523958A (en) * 2000-08-05 2004-11-26 Glaxo Group Ltd 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derviative as anti-inflammatory agents
IL155093A0 (en) 2000-09-29 2003-10-31 Glaxo Group Ltd Morpholin-acetamide derivatives for the treatment on inflammatory diseases
EP1341541A4 (en) 2000-11-16 2004-11-17 Alcon Mfg Ltd COMBINATION THERAPY FOR LOWERING AND CONTROLLING THE EYE PRESSURE
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
WO2002070490A1 (en) 2001-03-08 2002-09-12 Glaxo Group Limited Agonists of beta-adrenoceptors
EP1370521B1 (en) 2001-03-22 2007-12-19 Glaxo Group Limited Formanilide derivatives as beta2-adrenoreceptor agonists
MY137522A (en) * 2001-04-30 2009-02-27 Glaxo Group Ltd Novel anti-inflammatory androstane derivatives.
USRE44874E1 (en) 2001-09-14 2014-04-29 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
GB0125259D0 (en) * 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
ES2276038T3 (es) 2002-01-14 2007-06-16 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para su obtencion, formulaciones farmaceuticas que los contienen y usos de los mismos.
AU2003202044A1 (en) * 2002-01-15 2003-09-09 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
WO2003061651A1 (en) 2002-01-22 2003-07-31 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
EA008830B1 (ru) 2002-03-26 2007-08-31 Бёрингер Ингельхайм Фармасьютиклз, Инк. Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение
EP1490317A1 (en) 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
US6897224B2 (en) * 2002-04-02 2005-05-24 Schering Ag Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
EP1496892B1 (en) 2002-04-11 2011-01-26 Merck Sharp & Dohme Corp. 1h-benzo(f)indazol-5-yl derivatives as selective glucocorticoid receptor modulators
JP2005523920A (ja) 2002-04-25 2005-08-11 グラクソ　グループ　リミテッド フェネタノールアミン誘導体
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP4503436B2 (ja) 2002-07-08 2010-07-14 ファイザー・プロダクツ・インク 糖質コルチコイド受容体のモジュレーター
US7442554B2 (en) 2002-07-18 2008-10-28 Bristol-Myers Squibb Company Compositions and methods involving glucocorticoid receptor site II
PL375442A1 (en) 2002-07-18 2005-11-28 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
ATE403648T1 (de) 2002-08-21 2008-08-15 Boehringer Ingelheim Pharma Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
PL375993A1 (en) 2002-09-16 2005-12-12 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
JP4520309B2 (ja) 2002-09-20 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション 選択的糖質コルチコイド受容体調節剤としてのオクタヒドロ−２−Ｈ−ナフト［１，２−ｆ］インドール−４−カルボキサミド誘導体
JP2006506373A (ja) 2002-10-22 2006-02-23 グラクソ　グループ　リミテッド 医薬アリールエタノールアミン化合物
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
WO2004037773A1 (en) 2002-10-28 2004-05-06 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0316290D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
TW200524953A (en) 2005-08-01
JP4709751B2 (ja) 2011-06-22
JP2009514781A (ja) 2009-04-09
IL172776A0 (en) 2006-04-10
CA2531911A1 (en) 2005-01-20
US20080070880A1 (en) 2008-03-20
PT1644398E (pt) 2013-03-05
NO20060111L (no) 2006-01-24
US20060247219A1 (en) 2006-11-02
CN1849330A (zh) 2006-10-18
ATE467638T1 (de) 2010-05-15
IS8194A (is) 2005-12-22
ZA200600223B (en) 2007-04-25
MY140987A (en) 2010-02-12
EP1644398B1 (en) 2013-01-09
US20080015360A1 (en) 2008-01-17
US20080021231A1 (en) 2008-01-24
CY1110149T1 (el) 2015-01-14
NO20060110L (no) 2006-02-09
CN1845933B (zh) 2011-10-05
EP2380898A1 (en) 2011-10-26
MXPA06000443A (es) 2006-04-07
TWI338694B (en) 2011-03-11
CY1113836T1 (el) 2016-07-27
CA2531911C (en) 2011-11-01
IS2928B (is) 2015-09-15
AU2004255855B2 (en) 2009-07-30
MA27899A1 (fr) 2006-05-02
NZ544577A (en) 2009-07-31
AR045901A1 (es) 2005-11-16
JP2009513533A (ja) 2009-04-02
IL172777A (en) 2012-05-31
ES2433665T3 (es) 2013-12-12
PT1644397E (pt) 2010-07-01
IL172776A (en) 2015-05-31
DE602004027137D1 (de) 2010-06-24
HRP20130056T1 (hr) 2013-02-28
NZ544576A (en) 2009-06-26
BRPI0412526A (pt) 2006-09-19
NO333263B1 (no) 2013-04-22
IL210209A0 (en) 2011-03-31
SI1644397T1 (sl) 2010-09-30
CN1845933A (zh) 2006-10-11
CA2531905A1 (en) 2005-01-20
AR045900A1 (es) 2005-11-16
MY137944A (en) 2009-04-30
HRP20100359T1 (hr) 2010-07-31
EP1644397B1 (en) 2010-05-12
US7524970B2 (en) 2009-04-28
CN102372756A (zh) 2012-03-14
KR101029207B1 (ko) 2011-04-12
GB0316290D0 (en) 2003-08-13
RU2348645C2 (ru) 2009-03-10
KR101075324B1 (ko) 2011-10-19
SI1644398T1 (sl) 2013-04-30
HK1089186A1 (en) 2006-11-24
JP4709752B2 (ja) 2011-06-22
PL1644397T3 (pl) 2010-10-29
NO332041B1 (no) 2012-06-11
PL1644398T3 (pl) 2013-05-31
WO2005005452A1 (en) 2005-01-20
KR20060052807A (ko) 2006-05-19
ES2400821T3 (es) 2013-04-12
IS8193A (is) 2005-12-22
CA2531905C (en) 2012-05-08
TWI367888B (en) 2012-07-11
JP2011093929A (ja) 2011-05-12
US7638508B2 (en) 2009-12-29
IS2776B (is) 2012-03-15
AU2004255855A1 (en) 2005-01-20
RU2005141226A (ru) 2006-08-27
RU2359973C2 (ru) 2009-06-27
IS050094A (is) 2014-10-28
EP1644397A1 (en) 2006-04-12
US20100152148A1 (en) 2010-06-17
US20070043007A1 (en) 2007-02-22
DK1644397T3 (da) 2010-08-23
BRPI0412527A (pt) 2006-09-19
ES2343685T3 (es) 2010-08-06
MXPA06000442A (es) 2006-04-07
EP1644398A1 (en) 2006-04-12
US7288536B2 (en) 2007-10-30
IL172777A0 (en) 2006-04-10
US7291609B2 (en) 2007-11-06
HK1089185A1 (en) 2006-11-24
ZA200600226B (en) 2007-04-25
RU2005141064A (ru) 2006-08-10
AU2004255854A1 (en) 2005-01-20
WO2005005451A1 (en) 2005-01-20
EP2380898B1 (en) 2013-08-28
DK1644398T3 (da) 2013-02-04
MA27897A1 (fr) 2006-05-02
CN1849330B (zh) 2011-05-25
TW200524954A (en) 2005-08-01
AU2004255854B2 (en) 2009-10-22
IS2909B (is) 2014-11-15
KR20060052801A (ko) 2006-05-19

Similar Documents

Publication Publication Date Title
RU2009112207A (ru) Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью
RU2384580C2 (ru) Ингибиторы фосфатидилинозитол-3-киназы
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
HK1085390A1 (en) Solution for ungual and peri-ungual application and its use in preparation of a medicament treating dermatological diseases
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
JP2012514602A5 (ru)
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
KR19990044182A (ko) 말초 활성 통각과민 치료용 아편제
AR022461A1 (es) Compuesto de 5-hidroxiindol sustituido; proceso para su preparacion y composicion farmaceutica que lo contiene
DK1392329T3 (da) Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom
ATE318598T1 (de) Antioxidierende stabilisierungssysteme für pharmazeutische formulierungen
JP2011500779A (ja) 新規製剤
RU2006138495A (ru) Использование агонистов рецепторов, активируемых пролифератором пероксисомы дельта для лечения рс и других демиелинизирующих заболеваний
RU2002132882A (ru) Кожные композиции, содержащие кофермент q в качестве активного ингредиента
ATE218868T1 (de) Hustenhemmende, theobromine enthaltende zusammensetzungen
ES2184145T3 (es) Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida.
JP2008540534A (ja) 放出調節薬学組成物
CN1316965C (zh) 一种透明、隐形的外用给药载体
JP2003528919A5 (ru)
KR970706811A (ko) I형 알레르기성 질환의 예방 및 치료제(Preventive and remedy for type Ⅰ allergic diseases)
BRPI0407335A (pt) Agentes antibacterianos
UY26514A1 (es) &#34; composición para el tratamiento de tejidos danados&#34;.
AR015761A1 (es) Un derivado del acido 2-metilpropionico,una composicion farmaceutica que lo incluye, uso de un derivado del acido 2-metilpropionico y un procedimiento parala fabricacion de una composicion farmaceutica para la prevencion o el tratamiento de enfermedades
HRP20060040A2 (en) PURE D-(17α)-13-ETHYL-17-HYDROXY-18,19-DINORPREGN-4-ENE-20-YNE-3-ONE-3E- AND -3Z-OXIME ISOMERS, AS WELL AS PROCESS FOR THE SYNTHESIS OF THE MIXTURE OF ISOMERS AND THE PURE ISOMERS

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20120514